Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland

International Journal of Cancer

Volumn 123, Issue 6, 2008, Pages 1344-1349

  Leinonen, Maarit ^a   Kotaniemi Talonen, Laura ^a   Anttila, Ahti ^a   Dyba, Tadeusz ^a   Tarkkanen, Jussi ^b   Nieminen, Pekka ^b  

^a FINNISH CANCER REGISTRY   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Age; Cervical cancer; High risk HPV; Prevalence; Screening

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; CONDYLOMA ACUMINATUM; DEMOGRAPHY; DEVELOPED COUNTRY; DNA DETERMINATION; EARLY CANCER; FEMALE; FINLAND; HIGH RISK PATIENT; HUMAN; INFECTION RATE; ONCOGENE; PAPILLOMA VIRUS; PRIORITY JOURNAL; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; VIRUS ETIOLOGY; VIRUS INFECTION; WART VIRUS;

ADULT; AGE DISTRIBUTION; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; FINLAND; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 49749093858     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23670     Document Type: Article

References (37)

1. Anttila A, Pukkala E, Soderman B, Kallio M, Nieminen P, Hakama M. Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 1999;83:59-65.
2. Finnish Cancer Registry. Cancer incidence in Finland 2004 and 2005. Helsinki: Cancer Society of Finland, 2007. Publication No. 72.
3. International Agency for Research on Cancer. IARC Monographs on the evaluation of carcinogenic risks to humans. Lyon: IARC Press, 2007.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
5. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
6. Kotaniemi-Talonen L, Nieminen P, Anttila A, Hakama M. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005;93:862-7.
7. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, et al. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006;119: 2677-84.
8. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366:991-8.
9. Cuschieri KS, Cubie HA, Whitley MW, Seagar AL, Arends MJ, Moore C, Gilkisson G, McGoogan E. Multiple high risk HPV infections are common in cervical neoplasia and young women in a cervical screening population. J Clin Pathol 2004;57:68-72.
10. Forslund O, Antonsson A, Edlund K, van den Brule AJ, Hansson BG, Meijer CJ, Ryd W, Rylander E, Strand A, Wadell G, Dillner J, Johansson B. Population-based type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol 2002;66:535-41.
11. Ronco G, Segnan N, Giorgi-Rossi P, Zappa M, Casadei GP, Carozzi F, Dalla Palma P, Del Mistro A, Folicaldi S, Gillio-Tos A, Nardo G, Naldoni C, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the New Technologies for Cervical Cancer randomized controlled trial. J Natl Cancer Inst 2006;98: 765-74.
12. Ronco G, Giorgi-Rossi P, Carozzi F, Dalla Palma P, Del Mistro A, De Marco L, De Lillo M, Naldoni C, Pierotti P, Rizzolo R, Segnan N, Schincaglia P, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomized controlled trial. Lancet Oncol 2006;7:547-55.
13. de Sanjose S, Almirall R, Lloveras B, Font R, Diaz M, Munoz N, Catala I, Meijer CJ, Snijders PJ, Herrero R, Bosch FX. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 2003;30:788-93.
14. Bulkmans NW, Rozendaal L, Snijders PJ, Voorhorst FJ, Boeke AJ, Zandwijken GR, van Kemenade FJ, Verheijen RH, v Groningen K, Boon ME, Keuning HJ, van Ballegooijen M, et al. POBASCAM, a population-based randomised controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94-101.
15. Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Nazeyrollas P, Gabriel R, Quereux C, Birembaut P. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;89:1616-23.
16. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362:1871-6.
17. Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, van den Akker E, Iftner T. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003;88:1570-7.
18. Anttila A, Nieminen P. Cervical cancer screening programme in Finland. Eur J Cancer 2000;36:2209-14.
19. Kotaniemi-Talonen L, Anttila A, Malila N, Tarkkanen J, Laurila P, Hakama M, Nieminen P. Screening with a primary human papillomavirus test does not increase detection of cervical cancer and intraepithelial neoplasia 3. Eur J Cancer 2008;44:565-71.
20. Anttila A, Hakama M, Kotaniemi-Talonen L, Nieminen P. Alternative technologies in cervical cancer screening: a randomised evaluation trial. BMC Public Health 2006;6:252.
21. Wacholder S. Binomial regression in GLIM: estimating risk ratios and risk differences. Am J Epidemiol 1986;123:174-84.
22. McCullagh P, Nelder JA. Generalized linear models. London: Chapman and Hall, 1989.
23. Auvinen E, Niemi M, Malm C, Zilliacus R, Trontti A, Fingerroos R, Lehtinen M, Paavonen J. High prevalence of HPV among female students in Finland. Scand J Infect Dis 2005;37:873-6.
24. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN, Miller S, Canjura-Clayton KL, Farhat S, Broering JM, Darragh TM. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004;364:1678-83.
25. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: A summary of meta-analyses. Vaccine 2006;24(Suppl 3):S78-S89.
26. Naucler P, Ryd W, Tomberg S, Strand A, Wadell G, Elfgren K, Radberg T, Strander B, Forslund O, Hansson BG, Rylander E, Dillner J. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-97.
27. Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S, Voorhorst FJ, Verheijen RH, van Groningen K, Boon ME, Ruitinga W, van Ballegooijen M, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764-72.
28. Ronco G, Ghisetti V, Segnan N, Snijders PJ, Gillio-Tos A, Meijer CJ, Merletti F, Franceschi S. Prevalence of human papillomavirus infection in women in Turin, Italy. Eur J Cancer 2005;41:297-305.
29. Hinkula M, Pukkala E, Kyyronen P, Laukkanen P, Koskela P, Paavonen J, Lehtinen M, Kauppila A. A population-based study on the risk of cervical cancer and cervical intraepithelial neoplasia among grand multiparous women in Finland. Br J Cancer 2004;90:1025-9.
30. Munoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS, Shah HV, Meijer CJ, Bosch FX. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet 2002;359:1093-101.
31. Castle PE, Schiffman M, Glass AG, Rush BB, Scott DR, Wacholder S, Dunn A, Burk RD. Human papillomavirus prevalence in women who have and have not undergone hysterectomies. J Infect Dis 2006;194:1702-5.
32. Castle PE, Rodriques AC, Porras C, Herrero R, Schiffman M, Gonzales P, Hildesheim A, Burk RD. A comparison of cervical and vaginal human papillomavirus. Sex Transm Dis 2007;34:849-55.
33. Kalliala I, Anttila A, Pukkala E, Nieminen P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ 2005;331:1183-5.
34. Harkki-Siren P, Sjoberg J, Makinen J, Heinonen PK, Kauko M, Tomas E, Laatikainen T. Finnish national register of laparoscopic hysterectomies: a review and complications of 1165 operations. Am J Obstet Gynecol 1997;176:118-22.
35. Arbyn M, Anttila A, Jordan J, Ronco G, Schenck U, Segnan N, Wiener HG, Herbert A, Daniel J, Karsa L. von, eds. European guidelines for quality assurance in cervical cancer screening, 2nd edn. Belgium: European Communities, 2008.
36. Hemminki E, Sevon T, Tanninen K, Pukkala E, Anttila A. Use of private gynaecologist does not relate to better prevention outcomes - an ecological analysis from Finland. BMC Health Serv Res 2006;6:27.
37. Arbyn M, Raifu AO, Autier P, Ferlay J. Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 2007;18:1708-15.